KalVista Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $28.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Serge Belanger has given his Buy rating due to a combination of factors surrounding KalVista Pharmaceuticals. The recent FDA approval of Ekterly has shifted the company’s focus to its U.S. launch, which is anticipated to begin soon with the product expected to be available by mid-month. This strategic move is significant as Ekterly is set to lead the market with a considerable head-start over other oral on-demand treatments for hereditary angioedema (HAE).
Furthermore, KalVista’s financial position is robust, ending FY2025 with approximately $221 million in cash, which is projected to support the launch and sustain operations into FY27. The company’s potential to transform the HAE treatment landscape and achieve peak sales in the $700 million range underpins the Buy rating and the price target of $28. These elements collectively suggest a promising outlook for KalVista Pharmaceuticals, justifying the positive recommendation.
Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, BioCryst, and Cytokinetics. According to TipRanks, Belanger has an average return of 2.0% and a 43.68% success rate on recommended stocks.
In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $20.00 price target.